help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on July 22, 2005, doi:10.1164/rccm.200502-218OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200502-218OCv1
172/8/1008    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saiman, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saiman, L.
American Journal of Respiratory and Critical Care Medicine Vol 172. pp. 1008-1012, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200502-218OC

Heterogeneity of Treatment Response to Azithromycin in Patients with Cystic Fibrosis

Lisa Saiman, Nicole Mayer-Hamblett, Preston Campbell, Bruce C. Marshall for the Macrolide Study Group*

Department of Pediatrics, Columbia University, New York, New York; Departments of Pediatrics, University of Washington, Seattle; Statistical Analysis Unit, Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle, Washington; and Cystic Fibrosis Foundation, Bethesda, Maryland

Correspondence and requests for reprints should be addressed to Lisa Saiman, M.D., M.P.H., Columbia University College of Physicians and Surgeons, 622 West 168th Street, PH4W-470, New York, NY 10032. E-mail: LS5{at}columbia.edu

Rationale: We recently reported a randomized, placebo-controlled trial of azithromycin in patients with cystic fibrosis (CF) that demonstrated a 6.2% improvement in the 168-d relative change in FEV1 among azithromycin participants compared with placebo participants.

Objectives: In the current analyses, heterogeneity of treatment response and the association between FEV1 and the risk of pulmonary exacerbations were investigated.

Methods: The time to first pulmonary exacerbation, hospitalization rates, and antibiotic use were compared between participants categorized by their relative change in FEV1 % predicted (>= 5 vs. < 5% improvement) at Day 168. Pulmonary function and exacerbation responses were compared in subgroups of participants characterized by long-term concomitant medications and baseline lung function.

Measurements: All available data from the 185 randomized participants in the azithromycin trial were included in these analyses.

Main Results: Compared with placebo participants, a reduced risk of pulmonary exacerbations was observed both among azithromycin participants with >= 5% and those with < 5% relative improvement in FEV1. Similarly, decreased hospitalization rates and decreased use of oral quinolone and nonquinolone antibiotics were observed in azithromycin participants regardless of improvement in FEV1. Subgroup analyses demonstrated that overall, participants on long-term aerosolized tobramycin and/or rhDNase had worse baseline lung function, but still benefited from azithromycin, as evidenced by a lower risk of exacerbations.

Conclusions: Azithromycin participants experienced benefits in exacerbation parameters regardless of FEV1 response or subgroup. These data have implications for clinical practice and the design of clinical trials.

Key Words: antibiotic • azithromycin • cystic fibrosis • macrolide • Pseudomonas aeruginosa




This article has been cited by other articles:


Home page
 Eur Respir JHome page
P. A. J. Crosbie and M. A. Woodhead
Long-term macrolide therapy in chronic inflammatory airway diseases
Eur. Respir. J., January 1, 2009; 33(1): 171 - 181.
[Abstract] [Full Text] [PDF]

Home page
 J Intensive Care MedHome page
T. M. Kremer, R. G. Zwerdling, P. H. Michelson, and B. P. O'Sullivan
Intensive Care Management of the Patient With Cystic Fibrosis
J Intensive Care Med, May 1, 2008; 23(3): 159 - 177.
[Abstract] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. D. Starner, J. D. Shrout, M. R. Parsek, P. C. Appelbaum, and G. Kim
Subinhibitory Concentrations of Azithromycin Decrease Nontypeable Haemophilus influenzae Biofilm Formation and Diminish Established Biofilms
Antimicrob. Agents Chemother., January 1, 2008; 52(1): 137 - 145.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
L. B. Ware
Clinical Year in Review III: Asthma, Lung Transplantation, Cystic Fibrosis, Acute Respiratory Distress Syndrome
Proceedings of the ATS, September 15, 2007; 4(6): 489 - 493.
[Full Text] [PDF]

Home page
 ThoraxHome page
S. C Bell and P. J Robinson
Exacerbations in cystic fibrosis: 2 {middle dot} Prevention
Thorax, August 1, 2007; 62(8): 723 - 732.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. Cigana, B. M. Assael, and P. Melotti
Azithromycin Selectively Reduces Tumor Necrosis Factor Alpha Levels in Cystic Fibrosis Airway Epithelial Cells
Antimicrob. Agents Chemother., March 1, 2007; 51(3): 975 - 981.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
B. Enderby and I. Doull
Hypertonic saline inhalation in cystic fibrosis--salt in the wound, or sweet success?
Arch. Dis. Child., March 1, 2007; 92(3): 195 - 196.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
G. Tino
Clinical Year in Review IV: Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Infections, and Mycobacterial Disease
Proceedings of the ATS, November 1, 2006; 3(8): 650 - 653.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. J. Accurso
Update in cystic fibrosis 2005.
Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 944 - 947.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2005 American Thoracic Society 		  ATS Clinical Skills Tests